Entries by Uta Mommert

US$471m for cancer research fund

Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Argenx in cancer drug licensing deal

For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

Surviving the turmoil on capital markets

Early January saw a few indicators that stock markets might deliver some solid biotech results in 2016, even if it wasn’t destined to be a hallmark year for the industry. But then, in the weeks that followed, the situation began to deteriorate. Now it looks like European biotech companies might have to start coming to terms with a closing IPO window.

Operetta® CLS High-Content Analysis System

The Operetta CLS system enables scientists to gain deep biological insight into disease from common assays and complex applications using advanced cellular models, and to identify even subtle phenotypic changes through sensitive imaging and intuitive data analysis. 

The LabChip® GXII Touch System

The LabChip® GXII Touch System offers researchers an automated alternative to traditional methods by streamlining the multiple, manual steps of slab gel electrophoresis, while also providing the throughput and data quality essential in the biotherapeutics workflow. 

Sarstedt – Pipette Tips

Sarstedt offers an extensive range of certified and geometrically optimised pipette tips with and without filters for all common pipettes.